SPRYHealthcare · BiotechnologyThe 4 Wall Street analysts covering ARS Pharmaceuticals, Inc. hold a median 12-month price target of $23 — +307.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 15 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores ARS Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (53): Smaller than most of the companies we track.
Momentum (6): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SPRY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +307.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 June 2026 | Leerink Partners | Maintains | Outperform | $25 → $24 |
| 25 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 28 May 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 4 Sept 2025 | Roth Capital | Initiates | Buy | — |
| 7 Mar 2025 | Scotiabank | Initiates | Sector Outperform | — |
| 14 Jan 2025 | Raymond James | Maintains | Strong Buy | — |
| 13 Jan 2025 | Leerink Partners | Maintains | Outperform | — |
| 8 Oct 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Sept 2024 | Leerink Partners | Maintains | Outperform | — |
| 16 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 9 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Aug 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
| 13 Aug 2024 | Raymond James | Upgrade | Strong Buy | — |
| 25 July 2024 | Raymond James | Initiates | Outperform | — |
| 11 Mar 2024 | Wedbush | Reiterates | Outperform | — |
| 5 Mar 2024 | Leerink Partners | Upgrade | Outperform | — |
| 13 Nov 2023 | Wedbush | Maintains | Outperform | — |
| 21 Sept 2023 | Wedbush | Maintains | Outperform | — |
| 20 Sept 2023 | William Blair | Downgrade | Market Perform | — |
| 14 Aug 2023 | Wedbush | Reiterates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPRY appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 4% of US stocks
Cheaper than 26% of US stocks
Cheaper than 12% of US stocks
Cheaper than 74% of US stocks
Higher than 94% of US stocks
Higher than 89% of US stocks
Higher than 85% of US stocks
Higher than 11% of US stocks
Higher than 3% of US stocks
Higher than 7% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ARS Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Rosen Law Firm announced a securities fraud class action lawsuit on behalf of purchasers of ARS Pharmaceuticals (SPRY) securities between March 9, 2026 and June 24, 2026. A class action lawsuit has already been filed.
Why it matters — SPRY watchers would care because the company now faces an active securities fraud class action covering the Class Period.
Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. on behalf of investors who acquired ARS securities between March 9, 2026 and June 24, 2026. The lead plaintiff deadline is October 5, 2026, and affected investors are being invited to join the case.
Why it matters — The class action lawsuit and the associated Class Period raise potential legal and financial concerns for ARS Pharmaceuticals that SPRY watchers would want to monitor.
ARS Pharmaceuticals, Inc. (SPRY) held its Q2 2026 earnings call, with a transcript of the call published by Seeking Alpha. The call covered the company's second-quarter 2026 results and management commentary.
Why it matters — A SPRY watcher would look to the Q2 2026 earnings-call transcript for management's latest update on the company's financial results and business outlook.
ARS Pharmaceuticals outlined a revised commercial and spending strategy during its second-quarter 2026 earnings call, with new President and CEO Donn Casale emphasizing provider-focused promotion for its neffy intranasal epinephrine product, lower operating expenses, and an expected path to cash-flow breakeven by the end of 2027.
Why it matters — SPRY watchers would care because the company's strategy under new leadership points toward tighter cost control and a defined timeline to cash-flow breakeven, which bears on its financial trajectory.
ARS Pharmaceuticals reported a Q2 loss of $0.63 per share, wider than the Zacks Consensus Estimate of a $0.55 loss and versus a $0.46 loss a year ago. The report nevertheless topped revenue estimates.
Why it matters — A SPRY watcher would care because the quarterly loss came in worse than analysts expected, even as revenue exceeded estimates.
The 4 Wall Street analysts covering ARS Pharmaceuticals, Inc. have a median 12-month price target of $23, with estimates ranging from $17 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering ARS Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ARS Pharmaceuticals, Inc. 13 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, ARS Pharmaceuticals, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (53 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +307.1% from the last close, and Ticker Nerd's factor model ranks ARS Pharmaceuticals, Inc. 13 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ARS Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $30 over the next 12 months.
ARS Pharmaceuticals, Inc. returned -61.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes.
The most recent item we track (PRNewsWire, 17 Aug 2026): "SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit". Rosen Law Firm announced a securities fraud class action lawsuit on behalf of purchasers of ARS Pharmaceuticals (SPRY) securities between March 9, 2026 and June 24, 2026. A class action lawsuit has already been filed.
Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes. The company's primary purpose is to advance medical solutions for allergy-related indications, enhancing safety and convenience for patients affected by conditions such as allergic reactions requiring rapid intervention. Notable for its emphasis on creating user-friendly delivery mechanisms, Ars Pharmaceuticals tailors its offerings to both patients and healthcare professionals seeking reliable and effective emergency treatments. By addressing critical needs within the healthcare industry, Ars Pharmaceuticals plays a significant role in expanding options in allergy treatment and management. Its contributions to the medical field underscore its ongoing commitment to transforming therapeutic landscapes and meeting pressing health challenges.
CEO Mr. Donn Casale · 195 employees · United States · https://ars-pharma.com